İsmet İnce highlighted the pharmaceutical industry’s growth despite the challenging 2023.

İsmet İnce, the General Manager of TRPHARM, a leading company in the pharmaceutical industry, highlighted the industry’s growth despite the challenging year.

İnce pointed out that significant progress has been made in exports, stating, “Five years ago, when the sector’s export figures were around $800 million, today we have exceeded $2 billion. Turkey could reach figures of $20-30 billion in the long term.”

According to data from the Pharmaceutical Manufacturers Association of Türkiye, in the first ten months of 2023, the Turkish pharmaceutical market reached 167 billion TL in value and 2.2 billion units in quantity. Production increased by 1.9% compared to the same period of the previous year.

İsmet İnce emphasized that the earthquake disaster and economic fluctuations significantly affected the industry, stating, “2023 has been a year of dedication, understanding, and a bit of patience for our sector.”

Highlighting the industry’s significant progress in production, İnce emphasized that 90 out of every 100 boxes of medicine consumed in Turkey are produced domestically. Ince explained TRPharm’s goals for 2024 as follows: “Currently, we have more than 70 products, especially in rare diseases such as oncology, hematology, immunology, metabolism, eye care, children’s health, and medical aesthetics. We are working to add new products to our portfolio with over 50 partners. Our goal is to develop our original patented products.”

“In the coming period, our efforts to add new molecules to our portfolio in the areas we focus on will continue. After opening offices in İstanbul and Dubai, we recently opened our third office in Ghana. We will soon take the first step in our expansion to Europe. Many steps are included in our 2024 plan to increase our international presence. We continue our efforts with various partners worldwide to manufacture our products. We are continuing Phase 2 studies for two molecules we developed with our partners for Fanconi Anemia and Familial Mediterranean Fever.” he added.